naion and semaglutide A new MHRA update on with very rare reports of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION). #pharmacy #medicine #traineepharmacist Semaglutide and Nonarteritic Anterior Ischemic

This appetite-suppressing effect is one of the reasons semaglutide (in higher doses marketed as Wegovy) has been approved for weight management in the UK

Monitoring and follow-up: Regular follow-up during the first 3-6 months of therapy allows for symptom assessment, dose optimization, and early identification of complications

doi: 10.1210/endo.140.11.7143 30 DeaconCF

For patients experiencing side effects, dose reduction (tapering) often resolves nausea or gastrointestinal symptoms while preserving weight loss benefits

Safety considerations include risks like potential thyroid tumors, pancreatitis, and gastrointestinal disturbances